A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention

Regulations by 2FIRSTS
Oct.16.2024
A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention
FDA updates import alert on a product of Zhuhai Qisitech Co., Ltd., a subsidiary of Geekvape, for tobacco product violations.

Editor's Note:

After the publication of this article, some experts pointed out that Import Alert 98-06 is aimed at products rather than companies, that is, this time it targets the RAZ DC25000 ENDS products, not all products of Qisitech. 
For the sake of accuracy, this article has been specially updated.


 

Recently, the official website of the U.S. Food and Drug Administration (FDA) updated Import Alert 98-06. 2Firsts noticed that a product of Zhuhai Geekvape Technology Co., Ltd. (hereinafter referred to as "Geekvape"), was included in the latest import alert list.

A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention
Information disclosed on the FDA website for Zhuhai Qisitech Co., Ltd. | Image source: FDA website

 

According to the FDA website, ZHUHAI QISITECH CO., LTD was listed in the "Import Alert 98-06" also known as the "Red List" updated on September 26th, titled "Detention Without Physical Examination of New Tobacco Products Without Required Marketing Authorization".

A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention
ZhuHai QiSitech Co., Ltd.'s address matches the one published on the FDA official website. | Image source: Tianyancha

 

Comparison between information released by the FDA and information from Tianyancha shows that ZHUHAI QISITECH CO., LTD, also known as Zhuhai Qisi Manufacturing Co., Ltd., was established in 2021 and is a wholly-owned subsidiary of Shenzhen Geekvape Technology Co., Ltd. Geekvape is the brand owner of Geek Bar and Geek Vape, two of the most well-known e-cigarette brands in the United States, while Qisitech is one of the main contract manufacturers under Geekvape.

 

A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention
Zhuhai Qisi Intelligent Manufacturing Co., Ltd. is a wholly-owned subsidiary of Geekvape Technology Co., Ltd. in Shenzhen | Image source: Tianyancha

 

According to the FDA official website, departments can detain tobacco products listed on the Red List of this Import Alert without needing to conduct physical examinations. If a company wants to remove their products from the list, they must provide information to the relevant agencies to demonstrate that they have addressed the issues leading to non-compliance.

 

According to the above provisions, Qisitech's exports of the mentioned product to the United States will be detained until they are removed from Import Alert 98-06 list.

 

Compliance expert Kurt informed 2Firsts that Import Alert 98-06 is a list of companies that have submitted PMTAs (Pre-Market Tobacco Product Applications). Meanwhile, Import Alert 98-07, as listed on the FDA website, is focused on companies that have submitted PMTA applications.

 

2Firsts will continue to monitor the development of the event and provide timely updates on related coverage.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives